NYSE: HQL - Tekla Life Sciences Investors

Rentabilität für sechs Monate: -14.59%
Dividendenrendite: +12.12%
Sektor: Financials

Aktionsplan Tekla Life Sciences Investors

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Tekla Life Sciences Investors

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies.

weitere details
It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 1992-05-04
ISIN US87911K1007
Industry Capital Markets
Sector Financials
Валюта usd
Валюта отчета usd
Див.доход ао 15.06
Дивиденд ао 2.33
Сайт https://www.teklacap.com/hql.html
Цена ао 13.01
Preisänderung pro Tag: -0.7704% (12.98)
Preisänderung pro Woche: -1.98% (13.14)
Preisänderung pro Monat: -4.1% (13.43)
Preisänderung über 3 Monate: -4.59% (13.5)
Preisänderung über sechs Monate: -14.59% (15.08)
Preisänderung pro Jahr: -5.5% (13.63)
Preisänderung über 3 Jahre: -21.03% (16.31)
Preisänderung über 5 Jahre: -22.97% (16.72)
Preisänderung seit Jahresbeginn: -5.29% (13.6)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 4.88 3
P/BV 0.9204 9
P/E 4.96 10
EV/EBITDA 14.85 7
Gesamt: 8.63

Effizienz

Name Bedeutung Grad
ROA, % 19.76 6
ROE, % 19.8 6
Gesamt: 5.17

Dividenden

Name Bedeutung Grad
Div yield, % 12.12 10
DSI 0.8571 8.57
Gesamt: 7.79

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -30.15 0
Rentabilität Ebitda, % -131.71 0
Rentabilität EPS, % -41.09 0
Gesamt: 0
Weitere Details

Weitere Details

Institutionen Volumen Aktie, %
Saba Capital Management, L.P. 1421300 5.42
Cornerstone Advisors, LLC 494340 1.89
1607 Capital Partners, LLC 480179 1.83
Allspring Global Investments Holdings, LLC 454154 1.73
Morgan Stanley 430266 1.64
AQR Arbitrage LLC 384231 1.47
Clough Capital Partners, LP 375410 1.43
RPO LLC 338542 1.29
Needham Investment Management, L.L.C. 313792 1.2
Flagship Harbor Advisors, LLC 264003 1.01

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
Saba Closed End Funds ETF 2.8917 17.31 2.29022
Amplify High Income ETF 2.263 6.94 2.77149
First Trust Income Opportunities ETF 0.4681 18.3 2.48805
1.8714.182.52



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Daniel R. Omstead M.S, Ph.D. Principal Executive Officer, President and Trustee N/A 1953 (72 Jahr)
Mr. Peter Branner Chief Investment Officer N/A 1964 (61 Jahr)

Adresse: United States, Boston. MA, 100 Federal Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.teklacap.com/hql.html